Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Inactivated vs Live Attenuated HAV Vaccines
NCT02601040Phase 4Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Nov 2011
- Primary completion
- Jun 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of hepatitis A vaccine inactivated in hepatitis A (HAV), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Changes of hepatitis A antibody concentration at 37 months. Started Nov 2011; status: completed.
02
Drugs
hepatitis A vaccine inactivated
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on NCT02601040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601040.